Colorectal cancer biomarkers on agenda of Spain's royal academy
This article was originally published in Clinica
The role of biomarkers in the care of metastatic colorectal cancer was the subject of a scientific meeting at Spain's royal academy of medicine (RANM) this week in Madrid. Papers presented by RANM members Eduardo Díaz Rubio and Emilio S�nchez de la Concha formed the basis of the debate.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.